Penn Capital Management Company LLC Boosts Holdings in ANI Pharmaceuticals, Inc. $ANIP

Posted by Geri Gentry on May 27th, 2026

Penn Capital Management Company LLC increased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 2,058.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 137,394 shares of the specialty pharmaceutical company’s stock after buying an additional 131,030 shares during the quarter. Penn Capital Management Company LLC’s holdings in ANI Pharmaceuticals were worth $10,858,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ANIP. Hantz Financial Services Inc. raised its stake in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares during the period. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. State of Wyoming bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. Federated Hermes Inc. bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $93,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in ANI Pharmaceuticals by 30.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock worth $86,000 after acquiring an additional 253 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

ANIP has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $107.33.

View Our Latest Report on ANI Pharmaceuticals

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $81.41 on Wednesday. ANI Pharmaceuticals, Inc. has a 12 month low of $57.33 and a 12 month high of $99.50. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of 20.61 and a beta of 0.46. The company’s 50 day moving average is $78.32 and its two-hundred day moving average is $79.85. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s revenue was up 20.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current year.

Insider Activity

In other news, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the sale, the director owned 38,432 shares in the company, valued at $3,098,772.16. This trade represents a 20.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Ori Gutwerg sold 2,772 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total transaction of $220,374.00. Following the sale, the senior vice president owned 78,696 shares in the company, valued at approximately $6,256,332. The trade was a 3.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 91,427 shares of company stock valued at $7,089,066. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

(Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.